<DOC>
	<DOCNO>NCT01315847</DOCNO>
	<brief_summary>The purpose study determine receptor occupancy ( RO ) associate telcagepant ( MK-0974 ) administration base displacement [ 11C ] MK-4232 CGRP receptor brain use PET . The study enrol healthy participant ( Part I ) migraine patient ( Part III ) . Due protocol amendment , study Part II conduct .</brief_summary>
	<brief_title>Positron Emission Tomography ( PET ) Study Brain Calcitonin Gene-Related Peptide ( CGRP ) Receptor Occupancy After Telcagepant Administration ( MK-0974-067 )</brief_title>
	<detailed_description>For 1120 mg ( i.e. , maximal ) telcagepant dose , [ 11C ] MK-4232 administer PET scan start ~3 hour post telcagepant coincide Tmax 1120 mg dose . For 140 mg ( i.e. , therapeutic ) telcagepant dose , [ 11C ] MK-4232 administer PET scan start ~2 hour post telcagepant correspond time clinical efficacy measurement telcagepant migraine treatment Phase III study .</detailed_description>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>Participant ( Part III ) agree use ( partner use ) highly effective method birth control within project duration study Participant Body Mass Index ( BMI ) ≤32 kg/m2 prestudy visit Participant ( Part III ) history migraine without aura &gt; 1 year least 1 ≤8 moderate severe migraine attack per month last 3 month prior screen Participant judge good health ( apart migraine ) base medical history , physical examination , vital sign measurement , laboratory safety test Participant clinically significant abnormality electrocardiogram ( ECG ) Participant nonsmoker and/or use nicotine nicotine containing product least approximately 6 month Participant willing comply study restriction willing allow investigator place arterial catheter radial artery . Participant mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 year ( participant situational depression past 6 12 month , currently , may enrol discretion investigator ) Participant history illness , opinion study investigator , might confound result study pose additional risk subject participation study Participant estimate creatinine clearance ≤80 mL/min Participant history stroke , chronic seizure , major neurological disorder Participant history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Participant history neoplastic disease except 1 ) adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix 2 ) malignancy successfully treat ≥10 year prior prestudy ( screen ) visit , judgment investigator treat physician , appropriate followup reveal evidence recurrence time treatment time prestudy ( screen ) visit For Part III : Participant nursing mother , difficulty distinguish his/her migraine attack tension interval headache , history predominantly mild migraine attack migraine usually resolve spontaneously less 4 hour , basilar hemiplegic migraine headache , 15 headachedays per month take medication acute headache 10 day per month 3 month prior screen , take migraine prophylactic medication , &gt; 50 year age migraine onset , , opinion investigator , confound pain syndrome , psychiatric condition uncontrolled major depression , dementia significant neurological disorder migraine , liver function test , specifically alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) Alkaline Phosphatase upper limit normal prestudy ( screen ) visit recheck within 4 week prior Day 1 , take strong moderate Cytochrome P450 3A4 ( CYP3A4 ) inhibitor Ketoconazole , Diltiazem Verapamil Participant unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy Participant consumes excessive amount alcohol Participant consumes excessive amount , define great 6 serving caffeinated beverage per day Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy visit Participant history significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Participant currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 year Participant participate PET study study involve administration radioactive substance ionize radiation within 12 month prior prestudy visit Participant implant embed metal object fragment head body would present risk magnetic resonance imaging ( MRI ) scan Participant suffers claustrophobia would unable undergo MRI PET scan Any concern investigator regard safe participation participant study , ability subject tolerate procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>